Oral tacrolimus for severe recalcitrant atopic eczema [4]

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 6, 2003, Pages 1409-1410

  Schroer, Brian ^a   Lockey, Richard ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; COAL TAR; DOXEPIN; GLUCOCORTICOID; HYDROXYZINE; MONTELUKAST; PREDNISONE; TACROLIMUS; TRIAMCINOLONE;

ADULT; ATOPIC DERMATITIS; BALNEOTHERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFECT; HUMAN; IMMUNOTHERAPY; LETTER; MALE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

EID: 0037503950     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1509     Document Type: Letter

References (6)

1. Leung DYM. Immunopathogenesis of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:73-90.
2. Schneider LC. New treatment for atopic dermatitis. Immunol Allergy Clin North Am 2002;22:141-52.
3. Reutamo S. Tacrolimus: a new topical immunotherapy for atopic dermatitis. J Allergy Clinical Immunol 2001;107:445-8.
4. Panhans-Gros A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;107:345-52.
5. Hauk PJ, Leung DYM. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis. J Allergy Clin Immunol 2001;107:391-2.
6. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans, HA, Lightenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002;73:732-6.